CL2014002955A1 - Antagonista anticuerpo que se une a st2l y métodos de uso - Google Patents

Antagonista anticuerpo que se une a st2l y métodos de uso

Info

Publication number: CL2014002955A1
Authority: CL; Chile
Prior art keywords: st2l; binds; methods; antagonist antibody; antagonist
Prior art date: 2012-04-30

Application number

CL2014002955A

Other languages

English (en)

Inventor

Mark Tornetta

John Wheeler

Natalie Fursov

Karen Duffy

Catherine Healy

Roberta Lamb

Ravi Malaviya

Michael Pratta

Jinquan Lou

Michael Naso

Leroy Hall

Sheng-Jiun Wu

Original Assignee

Janssen Biotech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-30

Filing date

2014-10-30

Publication date

2015-01-16

2014-10-30 Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc

2015-01-16 Publication of CL2014002955A1 publication Critical patent/CL2014002955A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Microbiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Catching Or Destruction (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CL2014002955A 2012-04-30 2014-10-30 Antagonista anticuerpo que se une a st2l y métodos de uso CL2014002955A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261640238P	2012-04-30	2012-04-30
US201261640407P	2012-04-30	2012-04-30
US13/798,204 US9090694B2 (en)	2012-04-30	2013-03-13	ST2L antibody antagonists

Publications (1)

Publication Number	Publication Date
CL2014002955A1 true CL2014002955A1 (es)	2015-01-16

Family

ID=49477497

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002955A CL2014002955A1 (es)	2012-04-30	2014-10-30	Antagonista anticuerpo que se une a st2l y métodos de uso

Country Status (37)

Country	Link
US (4)	US9090694B2 (es)
EP (2)	EP2844292B1 (es)
JP (3)	JP6283354B2 (es)
KR (2)	KR20150008152A (es)
CN (2)	CN104411333B (es)
AR (1)	AR090909A1 (es)
AU (2)	AU2013256645B2 (es)
BR (1)	BR112014027165A2 (es)
CA (1)	CA2871948C (es)
CL (1)	CL2014002955A1 (es)
CO (1)	CO7240389A2 (es)
CR (1)	CR20140488A (es)
CY (1)	CY1122308T1 (es)
DK (1)	DK2844292T3 (es)
EA (2)	EA201891264A3 (es)
EC (1)	ECSP14025178A (es)
ES (1)	ES2755094T3 (es)
HR (1)	HRP20191884T1 (es)
HU (1)	HUE045864T2 (es)
IL (2)	IL235401B (es)
LT (1)	LT2844292T (es)
MX (2)	MX358134B (es)
MY (1)	MY166062A (es)
NI (1)	NI201400125A (es)
NZ (3)	NZ740221A (es)
PE (1)	PE20150641A1 (es)
PH (2)	PH12014502435A1 (es)
PL (1)	PL2844292T3 (es)
PT (1)	PT2844292T (es)
RS (1)	RS59511B1 (es)
SG (2)	SG11201407028WA (es)
SI (1)	SI2844292T1 (es)
SM (1)	SMT201900639T1 (es)
TW (3)	TWI700299B (es)
UA (1)	UA118336C2 (es)
UY (1)	UY34774A (es)
WO (1)	WO2013165894A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10053513B2 (en) *	2009-11-30	2018-08-21	Janssen Biotech, Inc.	Antibody Fc mutants with ablated effector functions
EP2506871B1 (en) *	2009-11-30	2016-10-19	Janssen Biotech, Inc.	ANTIBODY Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
US9090694B2 (en) *	2012-04-30	2015-07-28	Janssen Biotech, Inc.	ST2L antibody antagonists
AR091069A1 (es)	2012-05-18	2014-12-30	Amgen Inc	Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar)	2013-03-13	2020-07-05	Regeneron Pharma	الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
WO2014152195A1 (en)	2013-03-15	2014-09-25	Regeneron Pharmaceuticals, Inc.	Il-33 antagonists and uses thereof
JP2017503506A (ja)	2014-01-10	2017-02-02	アナプティスバイオインコーポレイティッド	インターロイキン−３３（ｉｌ−３３）に対する抗体
WO2015164354A1 (en)	2014-04-21	2015-10-29	The Childen's Hospital Of Philadelphia	Compositions and methods for treating cytokine-related disorders
AU2015280436A1 (en) *	2014-06-23	2017-02-02	Bionomics, Inc.	Antibodies that bind LGR4
KR20170080604A (ko)	2014-11-10	2017-07-10	제넨테크, 인크.	항-인터류킨-33 항체 및 그것의 용도
US20160168640A1 (en)	2014-11-10	2016-06-16	Genentech, Inc.	Therapeutic and diagnostic methods for il-33-mediated disorders
EP3265493B1 (en) *	2015-03-02	2024-01-10	180 Therapeutics LP	Method of treating a localized fibrotic disorder using an il-33 antagonist
CN108026172B (zh) *	2015-06-26	2022-04-29	赛诺菲生物技术公司	单克隆抗il-1racp抗体
WO2017124110A1 (en) *	2016-01-14	2017-07-20	Anaptysbio, Inc.	Inhibition of allergic reaction using an il-33 inhibitor
EP3241845A1 (en)	2016-05-06	2017-11-08	MAB Discovery GmbH	Humanized anti-il-1r3 antibodies
WO2018045210A1 (en) *	2016-09-02	2018-03-08	Therapeutics Lp 180	Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
WO2018045213A1 (en) *	2016-09-02	2018-03-08	180 Therapeutics Lp	Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
JOP20190093A1 (ar)	2016-10-28	2019-04-25	Lilly Co Eli	أجسام مضادة لـ il-33 واستخداماتها
TWI857389B (zh)	2016-12-01	2024-10-01	美商再生元醫藥公司	治療發炎症狀的方法
CR20190387A (es)	2017-02-10	2019-09-25	Genentech Inc	Anticuerpos contra triptasa, composiciones de estos y usos de estos
EP3601346A1 (en) *	2017-03-29	2020-02-05	H. Hoffnabb-La Roche Ag	Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018190990A1 (en)	2017-04-13	2018-10-18	Regeneron Pharmaceuticals, Inc.	Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
EP3401332A1 (en)	2017-05-08	2018-11-14	MAB Discovery GmbH	Anti-il-1r3 antibodies for use in inflammatory conditions
AU2018390881A1 (en)	2017-12-21	2020-07-02	F. Hoffmann-La Roche Ag	Antibodies binding to HLA-A2/WT1
AU2019218128A1 (en)	2018-02-09	2020-09-17	Genentech, Inc.	Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
IL307286A (en)	2018-04-11	2023-11-01	Regeneron Pharma	Methods and preparations for quantification of IL-33
MX2021005008A (es) *	2018-10-31	2021-06-15	Delinia Inc	Moduladores de celulas t reguladoras multivalentes.
KR102353568B1 (ko)	2018-11-14	2022-01-20	주식회사 헬릭스미스	안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CN110045131B (zh) *	2019-06-14	2019-09-03	迈威(上海)生物科技有限公司	用于测定人il-33/st2通路抑制剂的生物学活性的方法
TW202134261A (zh)	2019-11-04	2021-09-16	英商梅迪繆思有限公司	使用il-33拮抗劑之方法
US20220363748A1 (en)	2019-11-04	2022-11-17	Medimmune Limited	Anti il-33 therapeutic agent for treating renal disorders
EP4118114A1 (en)	2020-03-13	2023-01-18	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
CN115315527A (zh)	2020-03-13	2022-11-08	免疫医疗有限公司	用于治疗il33中存在风险等位基因的受试者的治疗方法
CA3176571A1 (en)	2020-04-06	2021-10-14	Medimmune Limited	Treating acute respiratory distress syndrome with il-33 axis binding antagonists
WO2021228091A1 (zh)	2020-05-12	2021-11-18	正大天晴药业集团股份有限公司	St2抗原结合蛋白
CN113501878B (zh) *	2021-02-03	2022-12-02	北京智仁美博生物科技有限公司	针对人tslp的多种抗体及其用途
AR125753A1 (es)	2021-05-04	2023-08-09	Agenus Inc	Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
TW202322850A (zh) *	2021-08-05	2023-06-16	美商美國禮來大藥廠	抗體最佳化
EP4430072A1 (en)	2021-11-10	2024-09-18	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
AU2023223413A1 (en) *	2022-02-24	2024-10-10	Sinomab Bioscience Limited	Bispecific binding proteins against alarmins and uses thereof
CN115838425B (zh) *	2022-08-31	2024-06-18	首都医科大学	一种靶向血管紧张素ii 1型受体细胞外第二环的抗体及其应用
CN120225564A (zh)	2022-09-21	2025-06-27	赛诺菲生物技术公司	人源化抗il-1r3抗体及其使用方法
CN119841936B (zh) *	2024-12-30	2025-09-30	中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心)	抗非洲猪瘟病毒p72蛋白中和性单克隆抗体5d2及其应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5869620A (en)	1986-09-02	1999-02-09	Enzon, Inc.	Multivalent antigen-binding proteins
DE3785186T2 (de)	1986-09-02	1993-07-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US6800738B1 (en)	1991-06-14	2004-10-05	Genentech, Inc.	Method for making humanized antibodies
US5932448A (en)	1991-11-29	1999-08-03	Protein Design Labs., Inc.	Bispecific antibody heterodimers
ES2227512T3 (es)	1991-12-02	2005-04-01	Medical Research Council	Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
AU690528B2 (en)	1992-12-04	1998-04-30	Medical Research Council	Multivalent and multispecific binding proteins, their manufacture and use
JPH09506508A (ja)	1993-12-03	1997-06-30	メディカルリサーチカウンシル	組換え結合タンパク質およびペプチド
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
AUPO591797A0 (en)	1997-03-27	1997-04-24	Commonwealth Scientific And Industrial Research Organisation	High avidity polyvalent and polyspecific reagents
WO1997014719A1 (en)	1995-10-16	1997-04-24	Unilever N.V.	A bifunctional or bivalent antibody fragment analogue
EP1983044B1 (en)	1996-10-10	2016-08-10	Life Technologies Corporation	Animal cell culture media comprising plant-derived nutrients
GB9727172D0 (en)	1997-12-24	1998-02-25	Univ Glasgow	Reagents specific for st2l and uses therefor
DE19819846B4 (de)	1998-05-05	2016-11-24	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Multivalente Antikörper-Konstrukte
GB9911569D0 (en)	1999-05-18	1999-07-21	Oxford Biomedica Ltd	Antibodies
US6323334B1 (en)	1999-09-24	2001-11-27	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001070817A1 (fr)	2000-03-21	2001-09-27	Medical & Biological Laboratories Co., Ltd.	Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant
ES2405944T3 (es)	2000-11-30	2013-06-04	Medarex, Inc.	Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
ES2727425T3 (es) *	2000-12-12	2019-10-16	Medimmune Llc	Moléculas con semividas prolongadas, composiciones y usos de las mismas
US6833441B2 (en)	2001-08-01	2004-12-21	Abmaxis, Inc.	Compositions and methods for generating chimeric heteromultimers
US6649055B1 (en)	2002-05-07	2003-11-18	The United States Of America As Represented By The United States Department Of Energy	Pump station for radioactive waste water
WO2004111233A1 (ja)	2003-06-11	2004-12-23	Chugai Seiyaku Kabushiki Kaisha	抗体の製造方法
JP2007522118A (ja) *	2004-01-30	2007-08-09	ペプリンバイオリピッズピーティーワイエルティーディー	治療用分子および担体分子
NZ549040A (en)	2004-02-17	2009-07-31	Schering Corp	Use for interleukin-33 (IL33) and the IL-33 receptor complex
CA2587627A1 (en)	2004-11-15	2006-05-26	Eli Lilly And Company	Desacyl ghrelin antibodies and therapeutic uses thereof
WO2006106905A1 (ja)	2005-03-31	2006-10-12	Chugai Seiyaku Kabushiki Kaisha	会合制御によるポリペプチド製造方法
EP1999154B1 (en)	2006-03-24	2012-10-24	Merck Patent GmbH	Engineered heterodimeric protein domains
EP2035456A1 (en)	2006-06-22	2009-03-18	Novo Nordisk A/S	Production of bispecific antibodies
US7560530B1 (en)	2006-07-20	2009-07-14	Schering Corporation	IL-33 receptor
WO2008022295A2 (en)	2006-08-18	2008-02-21	Novartis Ag	Prlr-specific antibody and uses thereof
ES2667863T3 (es)	2007-03-29	2018-05-14	Genmab A/S	Anticuerpos biespecíficos y métodos de producción de los mismos
US20100260770A1 (en)	2007-05-18	2010-10-14	Medimmune, Llc	Il-33 in inflammatory disease
US8748356B2 (en)	2007-10-19	2014-06-10	Janssen Biotech, Inc.	Methods for use in human-adapting monoclonal antibodies
WO2009085462A1 (en)	2007-12-19	2009-07-09	Centocor, Inc.	Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
DE102007061963A1 (de)	2007-12-21	2009-06-25	Merck Patent Gmbh	Pyridazinonderivate
PL2235064T3 (pl)	2008-01-07	2016-06-30	Amgen Inc	Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
CA2722466A1 (en)	2008-04-29	2009-11-05	Tariq Ghayur	Dual variable domain immunoglobulins and uses thereof
CN102307594A (zh)	2009-01-06	2012-01-04	戴埃克斯有限公司	用激肽释放酶抑制剂治疗粘膜炎
US8817596B2 (en)	2009-01-09	2014-08-26	Futurewei Technologies, Inc.	Protecting ingress and egress of a label switched path
US7879978B2 (en) *	2009-03-31	2011-02-01	Centocor Ortho Biotech, Inc.	Macaca fascicularis ST2L
US9067986B2 (en)	2009-04-27	2015-06-30	Oncomed Pharmaceuticals, Inc.	Method for making heteromultimeric molecules
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
EP2506871B1 (en) *	2009-11-30	2016-10-19	Janssen Biotech, Inc.	ANTIBODY Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
US20110206672A1 (en)	2010-02-25	2011-08-25	Melvyn Little	Antigen-Binding Molecule And Uses Thereof
PT2552961T (pt)	2010-03-30	2018-03-01	Janssen Biotech Inc	Anticorpos de il-25 humanizados
RU2625014C2 (ru)	2010-04-09	2017-07-11	Критикал Кэа Дайэгностикс, Инк.	Антитела против растворимого st-2 человека и способы анализа
KR101930964B1 (ko)	2010-04-20	2018-12-19	젠맵 에이/에스	이종이량체 항체 ｆｃ-함유 단백질 및 그의 생산 방법
CA2797981C (en)	2010-05-14	2019-04-23	Rinat Neuroscience Corporation	Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en)	2010-08-20	2012-02-22	Leadartis, S.L.	Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
CA2812389C (en)	2010-09-27	2019-12-31	John Kehoe	Antibodies binding human collagen ii
KR101973930B1 (ko)	2010-11-05	2019-04-29	자임워크스 인코포레이티드	Fc 도메인 내의 돌연변이를 갖는 안정한 이종이량체 항체 디자인
RU2597288C2 (ru)	2011-02-23	2016-09-10	Ф. Хоффманн-Ля Рош Аг	Антитела против человеческого il33r и их применение
US9090694B2 (en) *	2012-04-30	2015-07-28	Janssen Biotech, Inc.	ST2L antibody antagonists
AR091069A1 (es)	2012-05-18	2014-12-30	Amgen Inc	Proteinas de union a antigeno dirigidas contra el receptor st2

2013
- 2013-03-13 US US13/798,204 patent/US9090694B2/en not_active Expired - Fee Related
- 2013-03-13 US US13/798,226 patent/US9212227B2/en not_active Expired - Fee Related
- 2013-04-29 KR KR1020147033310A patent/KR20150008152A/ko not_active Withdrawn
- 2013-04-29 HU HUE13785158A patent/HUE045864T2/hu unknown
- 2013-04-29 WO PCT/US2013/038637 patent/WO2013165894A2/en active Application Filing
- 2013-04-29 SG SG11201407028WA patent/SG11201407028WA/en unknown
- 2013-04-29 NZ NZ74022113A patent/NZ740221A/en not_active IP Right Cessation
- 2013-04-29 SM SM20190639T patent/SMT201900639T1/it unknown
- 2013-04-29 JP JP2015510362A patent/JP6283354B2/ja not_active Expired - Fee Related
- 2013-04-29 EP EP13785158.0A patent/EP2844292B1/en active Active
- 2013-04-29 SG SG10201608525SA patent/SG10201608525SA/en unknown
- 2013-04-29 CN CN201380035058.3A patent/CN104411333B/zh not_active Expired - Fee Related
- 2013-04-29 PL PL13785158T patent/PL2844292T3/pl unknown
- 2013-04-29 CN CN201710188519.0A patent/CN107098973A/zh active Pending
- 2013-04-29 PE PE2014001920A patent/PE20150641A1/es active IP Right Grant
- 2013-04-29 LT LT13785158T patent/LT2844292T/lt unknown
- 2013-04-29 NZ NZ729913A patent/NZ729913A/en not_active IP Right Cessation
- 2013-04-29 EA EA201891264A patent/EA201891264A3/ru unknown
- 2013-04-29 BR BR112014027165A patent/BR112014027165A2/pt active Search and Examination
- 2013-04-29 ES ES13785158T patent/ES2755094T3/es active Active
- 2013-04-29 MX MX2014013200A patent/MX358134B/es active IP Right Grant
- 2013-04-29 CA CA2871948A patent/CA2871948C/en not_active Expired - Fee Related
- 2013-04-29 SI SI201331591T patent/SI2844292T1/sl unknown
- 2013-04-29 DK DK13785158.0T patent/DK2844292T3/da active
- 2013-04-29 KR KR1020207009560A patent/KR102147140B1/ko not_active Expired - Fee Related
- 2013-04-29 RS RS20191400A patent/RS59511B1/sr unknown
- 2013-04-29 EP EP19192657.5A patent/EP3597219A1/en not_active Withdrawn
- 2013-04-29 EA EA201491996A patent/EA031047B1/ru not_active IP Right Cessation
- 2013-04-29 AU AU2013256645A patent/AU2013256645B2/en not_active Ceased
- 2013-04-29 NZ NZ702136A patent/NZ702136A/en not_active IP Right Cessation
- 2013-04-29 PT PT137851580T patent/PT2844292T/pt unknown
- 2013-04-29 UA UAA201412805A patent/UA118336C2/uk unknown
- 2013-04-29 MY MYPI2014703188A patent/MY166062A/en unknown
- 2013-04-29 HR HRP20191884TT patent/HRP20191884T1/hr unknown
- 2013-04-30 UY UY0001034774A patent/UY34774A/es unknown
- 2013-04-30 TW TW108132205A patent/TWI700299B/zh not_active IP Right Cessation
- 2013-04-30 AR ARP130101485A patent/AR090909A1/es not_active Application Discontinuation
- 2013-04-30 TW TW102115440A patent/TWI589588B/zh not_active IP Right Cessation
- 2013-04-30 TW TW106115697A patent/TWI687440B/zh not_active IP Right Cessation
2014
- 2014-10-23 CR CR20140488A patent/CR20140488A/es unknown
- 2014-10-29 NI NI201400125A patent/NI201400125A/es unknown
- 2014-10-30 MX MX2018009430A patent/MX2018009430A/es unknown
- 2014-10-30 CL CL2014002955A patent/CL2014002955A1/es unknown
- 2014-10-30 PH PH12014502435A patent/PH12014502435A1/en unknown
- 2014-10-30 EC ECIEPI201425178A patent/ECSP14025178A/es unknown
- 2014-10-30 IL IL235401A patent/IL235401B/en active IP Right Grant
- 2014-10-30 CO CO14240957A patent/CO7240389A2/es unknown
2015
- 2015-11-12 US US14/939,624 patent/US9951137B2/en not_active Expired - Fee Related
2017
- 2017-04-20 AU AU2017202610A patent/AU2017202610B9/en not_active Ceased
- 2017-09-18 IL IL254569A patent/IL254569B/en active IP Right Grant
- 2017-11-06 JP JP2017213749A patent/JP6622274B2/ja not_active Expired - Fee Related
2018
- 2018-03-15 US US15/922,136 patent/US10450377B2/en not_active Expired - Fee Related
- 2018-08-29 PH PH12018501839A patent/PH12018501839A1/en unknown
2019
- 2019-05-24 JP JP2019097226A patent/JP2019162136A/ja not_active Withdrawn
- 2019-11-20 CY CY20191101218T patent/CY1122308T1/el unknown

Also Published As

Publication number	Publication date
US9212227B2 (en)	2015-12-15
SG10201608525SA (en)	2016-12-29
TWI589588B (zh)	2017-07-01
SI2844292T1 (sl)	2020-02-28
NI201400125A (es)	2016-11-30
KR20200037886A (ko)	2020-04-09
IL235401A0 (en)	2014-12-31
DK2844292T3 (da)	2019-10-21
PT2844292T (pt)	2019-11-26
EA201891264A3 (ru)	2019-02-28
RS59511B1 (sr)	2019-12-31
CR20140488A (es)	2015-01-12
TWI687440B (zh)	2020-03-11
CN104411333B (zh)	2017-04-26
JP6622274B2 (ja)	2019-12-18
US9090694B2 (en)	2015-07-28
IL254569A0 (en)	2017-11-30
ECSP14025178A (es)	2015-08-31
MX358134B (es)	2018-08-06
PH12018501839A1 (en)	2020-09-14
NZ740221A (en)	2019-11-29
PH12014502435A1 (en)	2015-01-12
SMT201900639T1 (it)	2020-01-14
US20190062439A1 (en)	2019-02-28
AU2013256645B2 (en)	2017-06-08
EP2844292A2 (en)	2015-03-11
AU2013256645A1 (en)	2014-11-13
US10450377B2 (en)	2019-10-22
PE20150641A1 (es)	2015-05-11
KR102147140B1 (ko)	2020-08-25
EA201491996A1 (ru)	2015-04-30
EA031047B1 (ru)	2018-11-30
AU2017202610B9 (en)	2019-06-20
BR112014027165A2 (pt)	2017-07-18
EA201891264A2 (ru)	2018-11-30
CY1122308T1 (el)	2021-01-27
TWI700299B (zh)	2020-08-01
CA2871948A1 (en)	2013-11-07
TW201345923A (zh)	2013-11-16
HK1208182A1 (en)	2016-02-26
WO2013165894A3 (en)	2014-03-27
PL2844292T3 (pl)	2020-03-31
AU2017202610B2 (en)	2019-06-13
EP2844292B1 (en)	2019-08-21
UA118336C2 (uk)	2019-01-10
ES2755094T3 (es)	2020-04-21
NZ702136A (en)	2017-03-31
US20170066831A1 (en)	2017-03-09
TW201730216A (zh)	2017-09-01
JP2018064560A (ja)	2018-04-26
JP2015516817A (ja)	2015-06-18
HUE045864T2 (hu)	2020-01-28
CA2871948C (en)	2020-09-08
US20130287777A1 (en)	2013-10-31
US9951137B2 (en)	2018-04-24
EP2844292A4 (en)	2016-05-25
JP2019162136A (ja)	2019-09-26
UY34774A (es)	2013-11-29
MY166062A (en)	2018-05-22
KR20150008152A (ko)	2015-01-21
CN107098973A (zh)	2017-08-29
LT2844292T (lt)	2019-11-25
CO7240389A2 (es)	2015-04-17
HRP20191884T1 (hr)	2020-02-07
NZ729913A (en)	2018-07-27
WO2013165894A2 (en)	2013-11-07
CN104411333A (zh)	2015-03-11
TW202019969A (zh)	2020-06-01
IL254569B (en)	2020-10-29
MX2018009430A (es)	2020-09-02
US20130336980A1 (en)	2013-12-19
IL235401B (en)	2020-10-29
JP6283354B2 (ja)	2018-02-21
EP3597219A1 (en)	2020-01-22
MX2014013200A (es)	2014-12-08
AR090909A1 (es)	2014-12-17
AU2017202610A1 (en)	2017-05-11
SG11201407028WA (en)	2015-01-29

Publication	Publication Date	Title
CL2014002955A1 (es)	2015-01-16	Antagonista anticuerpo que se une a st2l y métodos de uso
FR21C1061I2 (fr)	2022-11-18	Anticorps anti-angptl3 et utilisations de ceux-ci
FR24C1019I2 (fr)	2025-03-28	Anticorps anti-fcrn
CL2014003140A1 (es)	2015-02-27	Anticuerpos aislado que se une a ly6e; metodo de produccion; inmunoconjugado que lo contiene; formulacion farmaceutica que lo contiene y métodos de uso.
CO7000747A2 (es)	2014-07-21	Anticuerpos anti-lrp5 y métodos de uso
CL2016001556A1 (es)	2017-02-03	Anticuerpos anti-cd3 y métodos de uso
CL2014002086A1 (es)	2015-02-27	Anticuerpos cd47 y métodos de uso los mismos
BR112014018136A2 (pt)	2018-09-11	anticorpos ou uso e método para determinar
CO7020870A2 (es)	2014-08-11	Anticuerpos anti-htra1 y métodos de uso
CL2015000582A1 (es)	2015-11-06	Anticuerpos anti-mcam y métodos asociados de uso
CR20150618A (es)	2016-02-08	Anticuerpos receptores de antitransferina y métodos de uso
BR112014032193A2 (pt)	2017-06-27	métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico
CR20150329A (es)	2015-08-24	Inmunoglobulinas heterodiméricas
CL2015001266A1 (es)	2015-08-28	Anticuerpos de antihemaglutinina y métodos de uso.
EP2922874A4 (en)	2016-10-19	BISPECIFIC ANTIBODIES
EP2803662A4 (en)	2015-06-03	P2X4 Receptor Antagonists
PL2731677T3 (pl)	2018-08-31	Przeciwciała wiążące się z OX40 i ich zastosowania
DK2858671T3 (da)	2019-10-21	Antistofformulering
DK2890397T3 (da)	2019-08-05	Antiprolactinreceptor-antistofformulering
IL231931B (en)	2019-06-30	Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
EP2788377A4 (en)	2015-11-18	HER3 ANTIBODIES AND USES THEREOF
BR112014012590A2 (pt)	2017-06-20	anticorpos anti-cd98 e métodos de uso dos mesmos
BR112014002716A2 (pt)	2017-06-13	anticorpos anti-poliubiquitina e métodos de uso
FI20126017A7 (fi)	2014-01-31	Kauha ja sen käyttö
BR112014025037A2 (pt)	2018-07-31	anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente